Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Exosome-derived miR-210 involved in resistance to osimertinib and epithelial-mesenchymal transition in EGFR mutant non-small cell lung cancer cells.

Thoracic cancer - 1 Jun 2021

Hisakane Kakeru, Seike Masahiro, Sugano Teppei, Yoshikawa Akiko, Matsuda Kuniko, Takano Natsuki, Takahashi Satoshi, Noro Rintaro, Gemma Akihiko

Abstract excerpt

BACKGROUND: Osimertinib is a third-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) approved for the treatment of patients with EGFR-mutant non-small cell lung cancer (NSCLC). However, the mechanisms of acquired drug resistance to osimertinib have not as yet been clarified. Exosomes and microRNAs (miRNAs) are involved in carcinogenesis and drug resistance in human cancers. METHODS:...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acrylamides
Share to Aniline Compounds

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to Epithelial-Mesenchymal Transition

Share to Exosomes

Share to Indoles

Share to MicroRNAs

Share to Pyrimidines

Source

Open in PubMed Open full text

Identifiers

PMID: 33939301
DOI: 10.1111/1759-7714.13943
PMCID: PMC8169289

Genes

EGFR
PC

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Exosome-derived miR-210 involved in resistance to osimertinib and epithelial-mesenchymal transition in EGFR mutant non-small cell lung cancer cells.PMID 33939301Read ↗

Elevated exosome-derived miRNAs predict osimertinib resistance in non-small cell lung cancerSemantic proximity Read ↗

Elevated Exosome-derived Mirnas Predict Osimertinib Resistance in Non-small Cell Lung CancerSemantic proximity Read ↗

Exosomal microRNAs as potential biomarkers for osimertinib resistance of non-small cell lung cancer patientsSemantic proximity Read ↗

Exosomes miR-184 and miR-3913-5p are involved in Osimertinib resistance in non-small cell lung cancer patients with exon 21 L858R mutationSemantic proximity Read ↗

Exosomal non-coding RNAs-mediated EGFR-TKIs resistance in NSCLC with EGFR mutation.Semantic proximity Read ↗

MicroRNA-130a-3p regulates osimertinib resistance by targeting runt-related transcription factor 3 in lung adenocarcinomaSemantic proximity Read ↗

Intercellular transfer of exosomal wild type EGFR triggers osimertinib resistance in non-small cell lung cancer.Semantic proximity Read ↗

MiR-200c-3p suppression is associated with development of acquired resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in EGFR mutant non-small cell lung cancer via a mediating epithelial-to-mesenchymal transition (EMT) process.Semantic proximity Read ↗

ID1 mediates resistance to osimertinib in EGFR T790M-positive non-small cell lung cancer through epithelial-mesenchymal transition.Semantic proximity Read ↗

Loss of Key EMT-Regulating miRNAs Highlight the Role of ZEB1 in EGFR Tyrosine Kinase Inhibitor-Resistant NSCLC.Semantic proximity Read ↗

Characterization of circRNAs in established osimertinib‑resistant non‑small cell lung cancer cell linesSemantic proximity Read ↗

Osimertinib Induces the Opposite Effect of Proliferation and Migration in the Drug Resistance of EGFR-T790M Non-small Cell Lung Cancer Cells.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.